NeoGenomics Q4 revenue rises, adjusted EPS beats estimates

NeoGenomics

17/02/2026 12:13

Overview

Cancer diagnostics firm's Q4 revenue rose 11% yr/yr, driven by higher-value tests

Adjusted EPS for Q4 beat analyst expectations

Company successfully resolved RaDaR ST patent litigation

Outlook

NeoGenomics expects 2026 revenue between $793 mln and $801 mln

Company anticipates 2026 net loss between $63 mln and $50 mln

NeoGenomics sees modest MRD revenue contribution in 2026, substantial growth in 2027

Result Drivers

HIGHER VALUE TESTS - NeoGenomics attributed Q4 revenue growth to a shift towards higher-value tests, including NGS, and strategic reimbursement initiatives

NGS GROWTH - NGS grew 23% in Q4, significantly ahead of market growth, driven by innovation in the community channel

PATHLINE ACQUISITION - Revenue growth was supported by contributions from the Pathline acquisition, despite lower non-clinical revenue

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Adjusted EPS
Beat
$0.06
$0.04 (13 Analysts)
Q4 Adjusted Net Income
$8 mln
Q4 Net Income
-$10 mln
Q4 Adjusted EBITDA
$13 mln
Q4 Gross Profit
$83 mln
Q4 Operating Expenses
$97 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Neogenomics Inc is $14.00, about 23% above its February 13 closing price of $11.38

The stock recently traded at 69 times the next 12-month earnings vs. a P/E of 63 three months ago

Press Release: ID:nBw3MNlc4a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)